RecruitingPhase 3NCT07655804

Subcutaneous Calcitonin in Acute Herpes Zoster

The Prophylactic Value of Subcutaneous Calcitonin in Acute Herpes Zoster Patients: A Randomized Controlled Trial

Sponsor

Tanta University

Enrollment

168 participants

Start Date

Jul 1, 2026

Study Type

INTERVENTIONAL

Conditions

Calcitonin Acute Herpes Zoster Subcutaneous

Summary

This prospective randomized controlled study will be conducted to evaluate the effect of adding calcitonin to the standard treatment protocol in patients with acute herpes zoster infection.

Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Calcitonin and Saline for people with acute herpes zoster, calcitonin, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 50 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCalcitonin

patients will receive subcutaneous salmon calcitonin 100 IU (ampoule = 1 ml) daily for three weeks

OTHERSaline

patients will receive subcutaneous saline (1 ml) daily for three weeks.

Locations(1)

Tanta University Hospitals

Tanta, Gharbia Governorate, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07655804

Related Trials

Efficacy of Electroacupuncture for Acute Herpes Zoster-Associated Pain and Biomarker Evaluation

NCT075158851 location

Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury

NCT058056831 location